PHILADELPHIA, PA – Yesterday, GlycoMark, Inc. has agreed to pay $195,000 to settle allegations of violating the False Claims Act by encouraging customers to submit claims for the GlycoMark test after it was no longer approved for reimbursement to Medicare and Medicaid. The GlycoMark test was used to detect hyperglycemia and hyperglycemic excursions between 2016 and 2018.
According to the United States, GlycoMark knowingly caused to be submitted claims for GlycoMark tests that it knew were not covered by the Federal healthcare programs between November 1, 2016, and May 30, 2019. GlycoMark encouraged its customers to submit GlycoMark tests for Medicare reimbursement by printing and distributing marketing materials that stated “reimbursed by Medicare” and by displaying CPT code 84378 with no disclaimer that Medicare reimbursement is prohibited.
“Those who engage in these deceptive practices in the name of profits will be held accountable,” said U.S. Attorney Jacqueline C. Romero. The civil settlement resolves claims brought under the False Claims Act’s qui tam or whistleblower provisions. The investigation was conducted by the U.S. Department of Health and Human Services Office of Inspector General.